

Telephone (770) 488-4518, Fax (770) 488-4760. Email: [acbcyw@cdc.gov](mailto:acbcyw@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

**Purpose:** The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

**Matters To Be Considered:** The agenda will include discussions on current and emerging topics related to breast cancer in young women. These will include public health communication, breast cancer in young women digital and social media campaign, CDC updates, and updates from the field. Agenda items are subject to change as priorities dictate.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019-15593 Filed 7-22-19; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals

associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-IP20-001, Epidemiology, Prevention, and Treatment of Influenza and Other Respiratory Infections in Panama and Other Countries in the Americas.

**Date:** August 13, 2019.

**Time:** 10:00 a.m.—11:30 a.m., (EDT).

**Place:** Teleconference, Centers for Disease Control and Prevention, Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.

**Agenda:** To review and evaluate grant applications.

#### For Further Information Contact:

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, (404) 718-8833, [gca5@cdc.gov](mailto:gca5@cdc.gov).

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019-15587 Filed 7-22-19; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS). This meeting is open to the public; limited only by available seating. The meeting room accommodates approximately 78 people. Requests to make oral presentations should be submitted in writing to Gwen Mustaf, 301-458-4500,

[glm4@cdc.gov](mailto:glm4@cdc.gov), or Sayeedha Uddin, [isx9@cdc.gov](mailto:isx9@cdc.gov). All requests must contain the name, address, telephone number, and organizational affiliation of the presenter. Written comments should not exceed five single-spaced typed pages in length and must be received by August 14, 2019.

**DATES:** The meeting will be held on September 5, 2019, 11:00 a.m.—5:30 p.m., EDT, and September 6, 2019, 8:30 a.m.—1:00 p.m., EDT.

**ADDRESSES:** NCHS Headquarters, 3311 Toledo Road, Hyattsville, Maryland 20782.

#### FOR FURTHER INFORMATION CONTACT:

Sayeedha Uddin, M.D., M.P.H., Executive Secretary, NCHS/CDC, Board of Scientific Counselors, 3311 Toledo Road, Room 2627, Hyattsville, Maryland 20782, telephone (301) 458-4303, email [isx9@cdc.gov](mailto:isx9@cdc.gov).

**SUPPLEMENTARY INFORMATION:** All visitors must be processed in accordance with established federal policies and procedures. For foreign nationals or non-U.S. citizens, pre-approval is required (please contact Gwen Mustaf, 301-458-4500, [glm4@cdc.gov](mailto:glm4@cdc.gov) or Sayeedha Uddin, [isx9@cdc.gov](mailto:isx9@cdc.gov) at least 10 days in advance for requirements). All visitors are required to present a valid form of picture identification issued by a state, federal in international government. As required by the Federal Property Management Regulations, Title 41, Code of Federal Regulations, Subpart 101-20.301, all persons entering in or on Federal controlled property and their packages, briefcases, and other containers in their immediate possession are subject to being x-rayed and inspected. Federal law prohibits the knowing possession of the causing to be present of firearms, explosives and other dangerous weapons and illegal substances.

**Purpose:** This committee is charged with providing advice and making recommendations to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCHS, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS.

**Matters To Be Considered:** Day 1 meeting agenda includes welcome remarks and a Center update by NCHS leadership; update on Patient Centered Outcomes Research Trust Fund Drug Workgroup Report; update on Patient Centered Outcomes Research Trust Fund Projects; update on Evidence Based Policy Making; update on National Health Interview Survey Redesign. Day 2 meeting agenda

includes update on Maternal Mortality Data; report on NCHS Outreach Planning.

Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019-15588 Filed 7-22-19; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—PAR 18-812, NIOSH Member Conflict.

*Date:* October 29, 2019.

*Time:* 1:00 p.m.–4:00 p.m. EDT.

*Place:* Teleconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Nina Turner, Ph.D., Scientific Reviewer Officer, Office of Extramural Programs, 1095 Willowdale Road, Morgantown, West Virginia 26506, (304) 285-5976, [nxt2@cdc.gov](mailto:nxt2@cdc.gov).

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**

*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019-15591 Filed 7-22-19; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Board on Radiation and Worker Health (ABRWH or the Advisory Board), Subcommittee on Dose Reconstruction Review (SDRR), National Institute for Occupational Safety and Health (NIOSH)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Subcommittee for Dose Reconstruction Reviews (SDRR) of the Advisory Board on Radiation and Worker Health (ABRWH). This meeting is open to the public, but without a public comment period. The public is welcome to submit written comments in advance of the meeting, to the contact person below. Written comments received in advance of the meeting will be included in the official record of the meeting. The public is also welcome to listen to the meeting by joining the audio conference (information below). The audio conference line has 150 ports for callers.

**DATES:** The meeting will be held on September 12, 2019, 10:30 a.m. to 4:00 p.m. EDT.

**ADDRESSES:** Audio Conference Call via FTS Conferencing. The USA toll-free dial-in number is 1-866-659-0537; the passcode is 9933701.

**FOR FURTHER INFORMATION CONTACT:** Theodore Katz, MPA, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road NE, Mailstop E-20, Atlanta, Georgia 30329, Telephone (513) 533-6800, Toll Free 1 (800) CDC-INFO, Email [ocas@cdc.gov](mailto:ocas@cdc.gov).

#### SUPPLEMENTARY INFORMATION:

*Background:* The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the

new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines that have been promulgated by the Department of Health and Human Services (HHS) as a final rule; advice on methods of dose reconstruction, which have also been promulgated by HHS as a final rule; advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program; and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC).

In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, rechartered on February 12, 2018, pursuant to Executive Order 13708, and will terminate on September 30, 2019.

*Purpose:* The Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advise the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. SDRR was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction.

*Matters To Be Considered:* The agenda will include discussions on the following dose reconstruction program quality management and assurance activities: A draft report on the current progress and findings of dose reconstruction reviews for the Secretary, HHS; Dose reconstruction cases under review from Sets 25 and 26, possibly including cases involving Albuquerque Operations Office, Ames Laboratory, Aliquippa Forge, Battelle Memorial Institute, General Steel Industries, Hanford, Hooker Electrochemical, Los Alamos National Laboratory, Mallinckrodt Chemical Company, Nuclear Metals Inc., Pacific Northwest National Laboratories, Oak Ridge facilities (Y-12, K-25, X-10), Paducah Gaseous Diffusion Plant, Pantex Plant,